Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for Kathy Wood´┐Ż
-0.11 (-0.21%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 51.07 - 52.12
52 week 35.38 - 58.29
Open 51.84
Vol / Avg. 154,745.00/288,835.00
Mkt cap 1.78B
P/E     -
Div/yield     -
EPS -2.11
Shares 34.30M
Beta     -
Inst. own 88%
Aug 4, 2015
Q2 2015 Ophthotech Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Ophthotech Corp at Goldman Sachs Healthcare Conference
Jun 4, 2015
Ophthotech Corp Annual Shareholders Meeting
May 21, 2015
Ophthotech Corp Annual Shareholders Meeting (Estimated)
May 18, 2015
Ophthotech Corp at UBS Global Healthcare Conference
May 13, 2015
Ophthotech Corp at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Ophthotech Corp Earnings Call
May 11, 2015
Q1 2015 Ophthotech Corp Earnings Release
May 7, 2015
Ophthotech Corp at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 18.26% -237.98%
Operating margin 18.08% -195.14%
EBITD margin - -194.83%
Return on average assets 6.01% -27.42%
Return on average equity 19.77% -61.98%
Employees 72 -
CDP Score - -


1 Penn Plz Fl 19
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti- vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of polypoidal choroidal vasculopathy, a specific type of wet AMD; in patients who do not respond adequately to treatment with anti-VEGF monotherapy or for whom anti-VEGF monotherapy fails, and in combination with anti-VEGF therapy and Fovista for the treatment of anti-VEGF resistant wet AMD patients.

Officers and directors

David R. Guyer M.D. Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Samir C. Patel M.D. Vice Chairman of the Board, President
Age: 54
Bio & Compensation  - Reuters
Barbara Wood Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Douglas K. Kollmorgen Senior Vice President - Quality Assurance
Bio & Compensation  - Reuters
Harvey N. Masonson M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Loni da Silva Senior Vice President - Global Regulatory Affairs
Bio & Compensation  - Reuters
Todd N. Smith Senior Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
Kathy Galante Vice President of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Douglas G. Brooks Ph.D. Vice President - Manufacturing Development
Bio & Compensation  - Reuters
Jeffrey Nau Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters